Terms: = Kidney tumors AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
15 results:
1. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors.
Kim B; Lee S; Moon KC
Hum Pathol; 2023 Dec; 142():1-6. PubMed ID: 37797754
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological and molecular characterization of biphasic hyalinizing psammomatous renal cell carcinoma: further support for the newly proposed entity.
Wang XT; Xia QY; Fang R; Zhang RS; Ye SB; Li R; Wang X; Lu ZF; Ma HH; Zhou XJ; He HY; Zhao M; Rao Q
Hum Pathol; 2022 May; 123():102-112. PubMed ID: 35192800
[TBL] [Abstract] [Full Text] [Related]
3. Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS.
Wang KJ; Meng XY; Chen JF; Wang KY; Zhou C; Yu R; Ma Q
Oxid Med Cell Longev; 2021; 2021():8840590. PubMed ID: 33532038
[TBL] [Abstract] [Full Text] [Related]
4. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract] [Full Text] [Related]
5. Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.
He Y; Zhang P; Zhang D; Xia Z; Wang X; Deng S; Li H; Zhu H; Xu N; Liang S
Oncol Rep; 2018 Sep; 40(3):1467-1476. PubMed ID: 30015972
[TBL] [Abstract] [Full Text] [Related]
6. Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma.
Gaudio F; Pedote P; Asabella AN; Perrone T; Laddaga FE; Sindaco P; Cimmino A; D'Abbicco D; Pezzolla A; Rubini G; Specchia G
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e261-e266. PubMed ID: 29729983
[TBL] [Abstract] [Full Text] [Related]
7. clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
[TBL] [Abstract] [Full Text] [Related]
8. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
9. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
De Giorgi U; Rihawi K; Aieta M; Lo Re G; Sava T; Masini C; Baldazzi V; De Vincenzo F; Camerini A; Fornarini G; Burattini L; Rosti G; Moscetti L; Chiuri VE; Luzi Fedeli S; Ferrari V; Scarpi E; Amadori D; Basso U
J Geriatr Oncol; 2014 Apr; 5(2):156-63. PubMed ID: 24495699
[TBL] [Abstract] [Full Text] [Related]
10. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract] [Full Text] [Related]
11. Novel agents and approaches for advanced renal cell carcinoma.
Figlin R; Sternberg C; Wood CG
J Urol; 2012 Sep; 188(3):707-15. PubMed ID: 22818130
[TBL] [Abstract] [Full Text] [Related]
12. Expression and role of HMGA1 in renal cell carcinoma.
Takaha N; Sowa Y; Takeuchi I; Hongo F; Kawauchi A; Miki T
J Urol; 2012 Jun; 187(6):2215-22. PubMed ID: 22503056
[TBL] [Abstract] [Full Text] [Related]
13. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract] [Full Text] [Related]
14. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract] [Full Text] [Related]
15. Elevated akt activation and its impact on clinicopathological features of renal cell carcinoma.
Horiguchi A; Oya M; Uchida A; Marumo K; Murai M
J Urol; 2003 Feb; 169(2):710-3. PubMed ID: 12544348
[TBL] [Abstract] [Full Text] [Related]
